Study Results from National Institute of Technology Calicut Update Understanding of Cancer (1,2,3-triazole - [1,2,4]Triazolo[3,4- B ][1,3,4]Thiadiazine Hybrids: a Switch for Improvement of Antibreast Cancer Activity Targeting Epidermal...).

A recent study conducted by the National Institute of Technology Calicut in Kerala, India, focused on the development of anticancer agents targeting the epidermal growth factor receptor (EGFR). The researchers designed and synthesized a novel series of compounds and tested their in vitro anticancer activity against three human breast cancer cell lines. Two compounds, 7f and 7h, showed superior activity against the cell lines compared to the standard drug Erlotinib. These compounds also demonstrated high efficacy in inhibiting EGFR. Both experimental and in silico investigations suggest that compounds 7f and 7h hold promise as lead compounds for further drug design and development. [Extracted from the article]